The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Introduction Despite representing only 3% of the US population, immunocompromised (IC)
individuals account for nearly half of the COVID-19 breakthrough hospitalizations. IC …

Background Concerns have been raised regarding the reduced immunogenicity of vaccines
against COVID-19 in patients with autoimmune diseases treated with rituximab. However …

Objective Rheumatic disease patients on certain immunomodulators are at increased risk of
impaired humoral response to SARS-CoV-2 vaccines. We aimed to identify factors …

Patients with systemic lupus erythematosus (SLE) form a vulnerable group in terms of the
impact of the COVID-19 pandemic on disease management. We conducted this overview by …

Vaccines are important for protecting individuals at increased risk of severe infections,
including patients undergoing DMARD therapy. However, DMARD therapy can also …

Although COVID-19 outcomes have improved over the pandemic for patients with RA, some
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …

Many patients with systemic autoimmune rheumatic diseases (SARDs) require
immunosuppression to reduce disease activity, but this also has important possible …

Background Patients with autoimmune rheumatic diseases (ARD) are at a potentially higher
risk for COVID-19 infection complications. Given their inherent altered immune system and …

Since the emergence of the omicron (B. 1.1. 529) variant of SARS-CoV-2, the burden of
COVID-19 disease on health care has decreased, with rates of hospitalisation due to COVID …